Biophore India Pharmaceuticals Pvt. Ltd

Pharma Tech

Ranok Therapeutics | November 30, 2021

Ranok Therapeutics Co. Ltd., an emerging biopharmaceutical company focused on developing breakthrough therapies for cancer and other serious diseases, announced an agreement with Pfizer Inc. to apply and evaluate Ranok’s CHAMP™ platform technology on an undisclosed cancer target. Terms of the agreement were not disclosed. Ranok has developed a proprietary and innovative targeted protein degradation (TPD) platform technology, CHAMP™ (Chaperone-mediated Protein Deg...

Pharma Tech

PRNewswire | June 07, 2023

ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems (VLMS), and PharmEng Technology, a global ISO-certified consulting firm focused on life sciences, have partnered to provide a range of regulatory intelligence, GxP compliance, and digitized validation solutions for pharmaceutical, biotechnology, medical device, and nutraceutical companies across the globe. PharmEng Technology has staff all over the world serving companies of all sizes, prov...

Pharmacy Market

Twelve Consulting Group, | February 11, 2022

Twelve Consulting Group, a consultancy firm specializingin designing and delivering cloud-based solutions, has formalized its partnership with Celonis, the global leader in execution management. This partnership combines Twelve CG’s technology consulting expertise with Celonis’ market leading process mining and execution management capabilities, enabling customers to optimize their business operations, identify inefficiencies and unlock their full execution capacity. Read More

Business Insights

Acorda Therapeutics, Inc. | May 12, 2022

Acorda Therapeutics, Inc. and Biopas Laboratorie announced that they have entered into distribution and supply agreements to commercialize INBRIJA® in Latin America. INBRIJA is indicated in the United States for the intermittent treatment of episodic motor fluctuations in adult patients with Parkinson's disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor. Under the terms of the agreements, Acorda will receive a significant, double-digit, tiered percentage of ...